Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents.

[1]  P. Sarzi-Puttini,et al.  The therapeutic journey of biologic agents: There will be an end? , 2019, Pharmacological research.

[2]  K. Kalunian,et al.  Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. , 2019, JAMA.

[3]  P. Sarzi-Puttini,et al.  Systemic rheumatic diseases: From biological agents to small molecules. , 2019, Autoimmunity reviews.

[4]  P. Sarzi-Puttini,et al.  The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. , 2018, Rheumatology.

[5]  I. Olivieri,et al.  Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. , 2018, Rheumatology.

[6]  M. Genovese,et al.  Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial , 2018, The Lancet.

[7]  A. Barton,et al.  Rheumatoid arthritis , 2018, Nature Reviews Disease Primers.

[8]  P. Sarzi-Puttini,et al.  TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same? , 2017, Autoimmunity reviews.

[9]  E. Favalli,et al.  Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting. , 2017, Clinical and experimental rheumatology.

[10]  T. Horiuchi,et al.  Molecular mechanisms of action of anti‐TNF‐&agr; agents – Comparison among therapeutic TNF‐&agr; antagonists , 2018, Cytokine.

[11]  R. Caporali,et al.  The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. , 2017, Autoimmunity reviews.

[12]  Y. Shoenfeld,et al.  International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unm , 2017, Autoimmunity reviews.

[13]  P. Meroni,et al.  Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences , 2017, Clinical Rheumatology.

[14]  S. Gandolfo,et al.  AB0157 Trex 1 mutation in the members of a family with systemic lupus erythematosus and antiphospholipid syndrome , 2017 .

[15]  M. Dougados,et al.  Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis , 2017, Annals of the rheumatic diseases.

[16]  Mark Lunt,et al.  Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis , 2017, Annals of the rheumatic diseases.

[17]  G. Burmester,et al.  Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors , 2016, Arthritis & rheumatology.

[18]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[19]  P. Sarzi-Puttini,et al.  Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry , 2017, Clinical Rheumatology.

[20]  G. Burmester,et al.  Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study , 2016, The Lancet.

[21]  P. Ravaud,et al.  Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. , 2016, JAMA.

[22]  J. Raynauld,et al.  THU0035 Six Years Tocilizumab Use in Patients with Rheumatoid Arthritis with One Previous anti-TNF Agent Exposure: Comparison with Adalimumab and Etanercept from The Provincial Electronic Database and Registry Rhumadata® , 2016 .

[23]  J. Raynauld,et al.  THU0034 Use of Rituximab Compared To Anti-Tnf Agents as Second and Third-Line Therapy in Patients with Rheumatoid Arthritis. A 6-Year Follow-Up Report from The Rhumadata® Clinical Database and Registry , 2016 .

[24]  J. Kremer,et al.  Baricitinib in Patients with Refractory Rheumatoid Arthritis. , 2016, The New England journal of medicine.

[25]  R. Fischer-Betz,et al.  The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation , 2016, Annals of the rheumatic diseases.

[26]  B. Bannwarth,et al.  Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. , 2016, Rheumatology.

[27]  H. Bliddal,et al.  Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. , 2015, Rheumatology.

[28]  J. Kremer,et al.  Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry , 2015, Arthritis Research & Therapy.

[29]  C. Gabay,et al.  Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. , 2015, Rheumatology.

[30]  Theo Rispens,et al.  Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity , 2015, mAbs.

[31]  G. Burmester,et al.  Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial , 2014, Annals of the rheumatic diseases.

[32]  P. Emery,et al.  Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study , 2014, Annals of the rheumatic diseases.

[33]  G. Burmester,et al.  Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab , 2013, Annals of the rheumatic diseases.

[34]  I. Olivieri,et al.  Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review , 2014, Autoimmunity.

[35]  S. Kummerfeld,et al.  Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics , 2014, Arthritis Research & Therapy.

[36]  D. M. van der Heijde,et al.  Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis , 2014, Annals of the rheumatic diseases.

[37]  Tamas Koncz,et al.  Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial , 2013, The Lancet.

[38]  X. Mariette,et al.  Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective , 2012, Annals of the rheumatic diseases.

[39]  M. Dougados,et al.  Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. , 2012, Rheumatology.

[40]  G. Ferraccioli,et al.  To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50. , 2012, Autoimmunity reviews.

[41]  P. Sarzi-Puttini,et al.  Switching rheumatoid arthritis treatments: an update. , 2011, Autoimmunity reviews.

[42]  B. Dijkmans,et al.  Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. , 2011, JAMA.

[43]  W. Sandborn,et al.  Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[44]  D. Courvoisier,et al.  Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? , 2009, Annals of the rheumatic diseases.

[45]  P. Sarzi-Puttini,et al.  TNF‐α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice , 2009, Annals of the New York Academy of Sciences.

[46]  B. Dijkmans,et al.  Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. , 2009, Arthritis and rheumatism.

[47]  Mahboob Rahman,et al.  Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial , 2009, The Lancet.

[48]  L. Aarden,et al.  Dealing with immunogenicity of biologicals: assessment and clinical relevance , 2009, Current opinion in rheumatology.

[49]  A. Rubbert-Roth,et al.  Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review , 2009, Arthritis research & therapy.

[50]  J. Listing,et al.  Comparative effectiveness of tumour necrosis factor α inhibitors in combination with either methotrexate or leflunomide , 2009, Annals of the rheumatic diseases.

[51]  J. Kremer,et al.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial , 2008, Annals of the rheumatic diseases.

[52]  K. Bendtzen,et al.  Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. , 2007, Rheumatology.

[53]  E. Keystone,et al.  Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. , 2007, Arthritis and rheumatism.

[54]  B. Dijkmans,et al.  Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[55]  K. Bendtzen,et al.  Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. , 2006, Arthritis and rheumatism.

[56]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[57]  John Han,et al.  Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. , 2006, Arthritis and rheumatism.

[58]  B. Dijkmans,et al.  Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[59]  M. Dougados,et al.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. , 2005, The New England journal of medicine.

[60]  C. Wagner,et al.  Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus Monkeys , 2005, Journal of Pharmacology and Experimental Therapeutics.

[61]  B. Dijkmans,et al.  Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[62]  F. Wolfe,et al.  Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. , 2004, The Journal of rheumatology.

[63]  P. Lipsky,et al.  Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. , 2004, Arthritis and rheumatism.

[64]  D. Boumpas,et al.  Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit , 2004, Annals of the rheumatic diseases.

[65]  L. Klareskog,et al.  Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense , 2003, Annals of the rheumatic diseases.